TB-500 Peptide Powder Lyophilized Vial For Lab Research

Peptide

796043-06-6

C21H30N2O6S

438.54

Polypeptide

1.373±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

605.408±63.00 °C(Press: 760.00 Torr)(predicted)

14.773±0.10(predicted)

Actin-sequestering protein / 43-amino-acid peptide

Research compound — Not FDA approved (investigational: RGN-259 for dry eye / neurotrophic keratitis)

A naturally occurring 43-amino-acid peptide (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH) that binds G-actin (sequesters monomeric actin), preventing F-actin polymerization. Promotes cell migration, angiogenesis, wound healing, and anti-inflammatory responses via integrin-linked kinase (ILK) and HIF-1α/VEGF pathways. TB-500 is the synthetic fragment Ac-LKKTETQ (MW ~895) often sold under this CAS.

Thymosin Beta-4 is an actin-binding protein, not a receptor agonist. Functional activity is measured by actin sequestration (Kd ~0.7–1 μM) and cell migration assays, not EC₅₀.

Goldstein AL, et al. Vitam Horm. 2003;66:257–296. RegeneRx RGN-259 clinical program.DOI

NCT02974907; NCT02600429; NCT00376974

DB04951

PubChem

549LM7U24W

PubMed: Goldstein AL et al. (2003) — Review; ClinicalTrials.gov: ARISE-1 (NCT02974907)

Thymosin Beta-4 (TB-500) is NOT FDA-approved for human therapeutic use. RGN-259 (Tβ4 ophthalmic solution) is an investigational drug not yet approved. TB-500 sold on research-chemical marketplaces is a synthetic fragment and is not an approved medicine. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.